Roth MKM Reiterates Buy on Terns Pharma, Maintains $23 Price Target
Portfolio Pulse from richadhand@benzinga.com
Roth MKM analyst Dylan Dupuis has reiterated a 'Buy' rating on Terns Pharma (NASDAQ:TERN) and maintained a price target of $23.
June 30, 2023 | 2:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roth MKM analyst has reiterated a 'Buy' rating on Terns Pharma and maintained a price target of $23.
The reiteration of a 'Buy' rating by a Roth MKM analyst and the maintenance of a $23 price target indicates a positive outlook for Terns Pharma. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100